摘要
目的探讨盐酸特拉唑嗪联合前列舒通胶囊治疗Ⅲ型前列腺炎的临床效果。方法将120例Ⅲ型前列腺炎患者平均分为观察组和对照组，分别给予盐酸特拉唑嗪（2mg，每晚1次）＋前列舒通胶囊（3粒，每天3次）和盐酸特拉唑嗪（2mg，每晚1次）治疗，8周后按照美国国立卫生研究所（NIH）制定的前列腺症状评分标准（CPSI）、生活质量（QOL）评分及前列腺液常规。结果经过8周的治疗，观察组和对照组的NIH—CPSI评分、QOL评分及EPS常规中白细胞数目均有显著下降（P〈0．01），但观察组下降的程度均较对照组明显（P〈0．01）。结论盐酸特拉唑嗪联合前列舒通胶囊治疗Ⅲ型前列腺炎比单用盐酸特拉唑嗪疗效明显，值得临床推广。
Objectives To investigate the clinical effects of the terazosin Qianlieshu capsule treatment of type Ⅲprostatitis. Methods 120 patients with type Ⅲprostatitis patients were divided into observation group and control group were treated with terazosin （2 mg,1 night） ＋ （3 capsules Qianlieshu capsule three times daily） and hydrochloric acid terazosin （2 mg, 1 night） treatment, after 8 weeks in accordance with the U. S. National Institutes of Health （NIH） to develop prostate symptom score （CPSI）, quality of life （QOL） score and prostatic fluid routine. Results After eight weeks of treatment, observation group and control group of the NIH - CPSI score, QOL in score and EPS conventional leukocyte count are significantly decreased（ P 〈0.01 ）, but the degree of decline in the observation group than in the control group significantly（ P 〈 0.01 ）. Conclusions Terazosin forefront of spironolactone capsules in treatment of prostatitis type Ⅲterazosin efficacy than the single is worthy of clinical.
出处
《国际泌尿系统杂志》
2012年第4期469-471,共3页
International Journal of Urology and Nephrology
